Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 23;8(7):764.
doi: 10.3390/cells8070764.

Mesenchymal Stem Cells for Perianal Crohn's Disease

Michele Carvello  1 , Amy Lightner  2 , Takayuki Yamamoto  3 , Paulo Gustavo Kotze  4 , Antonino Spinelli  5   6
Affiliations
Review

Mesenchymal Stem Cells for Perianal Crohn's Disease

Michele Carvello et al. Cells. .

Abstract

Perianal fistulizing Crohn's disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents, reaches 50% of treated patients. More recently, the administration of mesenchymal stem cells (MSCs) have shown notable promising results in the treatment of PFCD. The aim of this review is to describe the rationale and the possible mechanism of action of MSC application for PFCD and the most recent results of randomized clinical trials. Furthermore, the unmet needs of the current administration process and the expected next steps to improve the outcomes will be addressed.

Keywords: Crohn’s disease; fistula; perianal; stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action of MSCs (courtesy of Cleveland Clinic, with permission).
Figure 2
Figure 2
ADMIRE randomized trial results of efficacy at week 24.
Figure 3
Figure 3
Long-term extension efficacy results of the ADMIRE randomized trial at week 52.
See this image and copyright information in PMC

References

    1. Chaparro M., Zanotti C., Burgueño P., Vera I., Bermejo F., Marín-Jiménez I., Yela C., López P., Martín M.D., Taxonera C., et al. Health care costs of complex perianal fistula in Crohn’s disease. Dig. Dis. Sci. 2013 doi: 10.1007/s10620-013-2830-7. - DOI - PubMed
    1. Aguilera-Castro L., Ferre-Aracil C., Garcia-Garcia-De-Paredes A., Rodriguez-De-Santiago E., Lopez-Sanroman A. Management of complex perianal crohn’s disease. Ann. Gastroenterol. 2017 doi: 10.20524/aog.2016.0099. - DOI - PMC - PubMed
    1. Molendijk I., Nuij V.J.A.A., Van Der Meulen-De Jong A.E., Van Der Woude C.J. Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm. Bowel Dis. 2014 doi: 10.1097/MIB.0000000000000148. - DOI - PubMed
    1. Schwartz D.A., Loftus E.V., Tremaine W.J., Panaccione R., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002 doi: 10.1053/gast.2002.32362. - DOI - PubMed
    1. Soltani A., Kaiser A.M. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis. Colon Rectum. 2010 doi: 10.1007/dcr.0b013e3181ce8b01. - DOI - PubMed